Literature DB >> 32602683

Prognostic Factors for Adverse Outcomes in COVID-19 Infection.

Zarir F Udwadia1, Awatansh R Tripathi2, Viral J Nanda2, Shashank R Joshi3.   

Abstract

Whilst COVID-19 infection generally run a mild course in up to 80% of those affected, a number of pre-existing co-morbidities determine the severity of infection and the outcome in an individual patient. The most important of these co-morbidities that have consistently emerged in studies from across the globe, are the patients age and sex. Other important co-morbidities that adversely affect outcomes include pre-existing diabetes, obesity, hypertension, chronic lung disease and malignancy. This comprehensive review discusses the impact of these co-morbidities and the role of laboratory predictors of poor patient outcomes. © Journal of the Association of Physicians of India 2011.

Entities:  

Mesh:

Year:  2020        PMID: 32602683

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  4 in total

1.  Long COVID Patient Symptoms and its Evaluation and Management.

Authors:  Deepak Sundar Shrestha; Richard Love
Journal:  JNMA J Nepal Med Assoc       Date:  2021-08-12       Impact factor: 0.556

2.  Effect of ABO blood groups on length of hospital stay according to age in Covid-19 patients.

Authors:  Vildan Gursoy; Suna Avci
Journal:  Hematol Transfus Cell Ther       Date:  2021-11-29

3.  Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study.

Authors:  Jennifer E Nyland; Nazia T Raja-Khan; Kerstin Bettermann; Philippe A Haouzi; Douglas L Leslie; Jennifer L Kraschnewski; Leslie J Parent; Patricia Sue Grigson
Journal:  Diabetes       Date:  2021-09-27       Impact factor: 9.461

4.  Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up.

Authors:  Rocío-V Gamboa-Cárdenas; Silvia Barzola-Cerrón; Denisse Toledo-Neira; Cristina Reátegui-Sokolova; Víctor Pimentel-Quiroz; Francisco Zevallos-Miranda; Graciela S Alarcón; Manuel Ugarte-Gil
Journal:  Clin Rheumatol       Date:  2021-06-30       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.